Movement disorders : official journal of the Movement Disorder Society · 2026
Longitudinal Iron Changes in the Substantia Nigra of Early-Stage Parkinson's Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Du Guangwei, Sica Christopher, de Jesus Sol, Kong Lan, Mailman Richard B, Huang Xuemei
Аннотация
BACKGROUND: Progression of substantia nigra pars compacta (SNc) iron content in early-stage Parkinson's patients (PD) is poorly understood.
OBJECTIVE: To determine if nigral iron measured by quantitative susceptibility mapping (QSM) with zero-referencing can track disease progression in early-stage PD.
METHODS: Thirty-four early-stage PD patients and 35 matched controls were recruited. Iron content in the SNc and related regions were obtained using QSM with zero-referencing at both baseline and 1-year follow-up, along with clinical metrics.
RESULTS: Of seven clinic metrics and five regional iron measures, only Movement Disorder Society-Unified Parkinson's Disease Rating Scale-Part II (MDS-UPDRS-II) (P = 0.046) and SNc iron (P = 0.0025 for cerebrospinal fluid zero-referencing; P = 0.014 for whole-brain zero-referencing) showed significant changes in PD subjects in the 1-year epoch. The changes in SNc iron were also correlated with changes in MDS-UPDRS-II (P = 0.004).
CONCLUSION: Nigral iron content measured by zero-referencing QSM can be used to track disease progression in early-stage PD over the 1-year epoch. © 2026 International Parkinson and Movement Disorder Society.
OBJECTIVE: To determine if nigral iron measured by quantitative susceptibility mapping (QSM) with zero-referencing can track disease progression in early-stage PD.
METHODS: Thirty-four early-stage PD patients and 35 matched controls were recruited. Iron content in the SNc and related regions were obtained using QSM with zero-referencing at both baseline and 1-year follow-up, along with clinical metrics.
RESULTS: Of seven clinic metrics and five regional iron measures, only Movement Disorder Society-Unified Parkinson's Disease Rating Scale-Part II (MDS-UPDRS-II) (P = 0.046) and SNc iron (P = 0.0025 for cerebrospinal fluid zero-referencing; P = 0.014 for whole-brain zero-referencing) showed significant changes in PD subjects in the 1-year epoch. The changes in SNc iron were also correlated with changes in MDS-UPDRS-II (P = 0.004).
CONCLUSION: Nigral iron content measured by zero-referencing QSM can be used to track disease progression in early-stage PD over the 1-year epoch. © 2026 International Parkinson and Movement Disorder Society.